08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Advanced Biomedical Systems, Biohit deal

Biohit acquired exclusive, worldwide development and commercialization rights to the UFT300 test for Helicobacter pylori infection from Advanced Biomedical for €350,000 ($472,605). UFT300 detects H. pylori urease activity in gastric biopsy specimens. The company said...